寶齡富錦生技股份有限公司
寶齡富錦生技股份有限公司（Panion & Bf Biotech Inc.）為一家跨足新藥研發、醫學美容、臨床檢測及感染控制的生技公司。公司最著名的研發成果為治療慢性腎臟病高磷血症的新藥「拿百磷（Nephoxil）」，已在全球多國上市。其他產品線包括皮膚醫學級保養品（抗老、防脫髮）、快篩檢測試劑（新冠、流感）、消毒感控產品及各類西藥學名藥。公司成立於 1976 年，總部位於台灣台北市。
該股 RSI(6) 為 48.2，處於中性區間，短線無明顯超買超賣訊號。股價站上5日均線，跌破20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=42.3）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | -13 | 0 | +3 | -10 |
| 08-10 | -8 | 0 | 0 | -8 |
| 08-07 | +56 | 0 | 0 | +56 |
| 08-06 | -23 | 0 | 0 | -23 |
| 08-05 | +22 | 0 | 0 | +22 |
| 08-04 | -16 | 0 | -2 | -18 |
| 08-03 | -19 | 0 | -2 | -21 |
| 07-31 | -51 | 0 | 0 | -51 |
| 07-30 | -28 | 0 | -3 | -31 |
| 07-29 | -22 | 0 | +1 | -21 |
| 07-28 | -26 | 0 | -7 | -33 |
| 07-27 | -18 | 0 | +2 | -16 |
| 07-24 | +11 | 0 | -1 | +10 |
| 07-23 | -58 | 0 | +8 | -50 |
| 07-22 | +2 | 0 | -2 | 0 |
| 07-21 | -23 | 0 | -8 | -30 |
| 07-20 | -27 | 0 | +2 | -25 |
| 07-17 | -107 | 0 | +3 | -104 |
| 07-16 | -3 | 0 | +1 | -2 |
| 07-15 | +68 | 0 | -3 | +65 |
| 07-14 | +19 | 0 | -1 | +18 |
| 07-13 | -46 | 0 | +1 | -45 |
| 07-09 | -58 | 0 | -2 | -60 |
| 07-08 | +110 | 0 | 0 | +110 |
| 07-07 | +117 | 0 | 0 | +117 |
| 07-06 | +7 | 0 | 0 | +7 |
| 07-03 | +159 | 0 | +1 | +160 |
| 07-02 | +12 | 0 | -2 | +10 |
| 07-01 | +85 | 0 | +1 | +86 |
| 06-30 | +60 | 0 | +1 | +61 |
| 06-29 | +40 | 0 | 0 | +40 |
| 06-26 | -42 | 0 | -2 | -44 |
| 06-25 | -19 | 0 | +1 | -18 |
| 06-24 | +22 | 0 | 0 | +22 |
| 06-22 | +43 | 0 | +2 | +45 |
| 06-18 | -20 | 0 | +7 | -13 |
| 06-17 | +7 | 0 | -4 | +3 |
| 06-16 | -1 | 0 | 0 | -1 |
| 06-15 | +9 | 0 | +1 | +10 |
| 06-12 | +91 | 0 | +1 | +92 |
| 06-10 | +87 | 0 | -1 | +86 |
| 06-09 | +9 | 0 | -2 | +7 |
| 06-08 | +1 | 0 | 0 | +1 |
| 06-04 | -2 | 0 | 0 | -2 |
| 06-03 | +27 | 0 | 0 | +27 |
| 06-02 | +59 | 0 | -2 | +57 |
| 06-01 | +39 | 0 | +2 | +41 |
| 05-29 | +1 | 0 | -1 | 0 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 1.33 億 | -43.4% | -4.0% |
| 2026/05 | 2.34 億 | +62.1% | +1.8% |
| 2026/04 | 1.45 億 | -3.5% | +7.0% |
| 2026/03 | 1.50 億 | -35.6% | +17.1% |
| 2026/02 | 2.33 億 | +70.1% | -4.5% |
| 2026/01 | 1.37 億 | -24.0% | +24.3% |
| 2025/12 | 1.80 億 | -22.6% | +14.9% |
| 2025/11 | 2.32 億 | +73.7% | -1.3% |
| 2025/10 | 1.34 億 | -1.4% | +2.6% |
| 2025/09 | 1.36 億 | -46.0% | +3.7% |
| 2025/08 | 2.51 億 | +73.5% | +4.6% |
| 2025/07 | 1.45 億 | - | -4.8% |